Trends in Breast Imaging Care: Improving Outcomes, Efficiency, and Experience
Hologic’s Jennifer Meade, division president of breast and skeletal care, discusses the focus for breast imaging in the near future and some latest technologies.
Hologic received 510(k) clearance from the U.S. Food & Drug Administration for its Genius AI Detection software this week during the Radiology Society of North America (RSNA) annual meeting. This move is one more development that is feeding growing trends in breast imaging, said Jennifer Meade, division president of breast and skeletal care for women’s imaging vendor Hologic.
Meade spoke with Diagnostic Imaging not only about some of Hologic’s more recent product offerings, but she also discussed feedback from the radiology community and some growing trends in breast imaging. In the coming years, she said, the industry can expect to see a greater focus on improved patient outcomes, workflow efficiency, and patient experience. In addition, she said developments and investments will continue around artificial intelligence, as well as personalized medicine.
With this latest FDA clearance, the Genius AI Detection software is set to follow that path, according to company information. It is designed to optimize workflow in four specific ways – by providing a case score that reflects confidence of malignancy, categorizing cases based on the number of lesions present, flagging the most concerning cases in less than a minute, and providing an estimate of how much time a radiologist can expect the image review to take.
For more RSNA coverage, click here.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
